New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:15 EDTBDSIBioDelivery Sciences randomized half the patients required for Clonidine study
BioDelivery Sciences International announced that it has randomized more than half of the planned number of patients required for its ongoing initial Phase 3 study of Clonidine Topical Gel, BDSI's proposed treatment for painful diabetic neuropathy. The intent of the study will be to demonstrate the efficacy and safety of Clonidine Topical Gel for the treatment of PDN. An interim analysis of the study, which will be based on the first 50% of patients entering the study, is now anticipated to occur in the Q3 of 2014. It was earlier projected based on estimated patient enrollment the interim analysis would occur in fourth quarter of this year. The purpose of the interim analysis is to confirm the assumptions regarding the study sample size and allow for an increase if needed.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
09:02 EDTBDSIAcceptance of NDA for Belbuca triggers $10M milestone payment to BDSI
Subscribe for More Information
07:31 EDTBDSIEndo, BioDelivery Sciences announce acceptance of NDA for Belbuca
Subscribe for More Information
February 20, 2015
08:21 EDTBDSISummer Street still feels Endo could acquire BioDelivery Sciences
Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use